Cargando…

Circulating Protein Biomarkers for Prognostic Use in Patients with Advanced Pancreatic Ductal Adenocarcinoma Undergoing Chemotherapy

SIMPLE SUMMARY: We investigated the connection between the levels of 92 circulating proteins and survival in patients with advanced pancreatic ductal adenocarcinoma. Serum samples from 363 patients with advanced pancreatic ductal adenocarcinoma were examined using the Olink Immuno-Oncology panel. Tw...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lindgaard, Sidsel C., Maag, Emil, Sztupinszki, Zsófia, Chen, Inna M., Johansen, Astrid Z., Jensen, Benny V., Bojesen, Stig E., Nielsen, Dorte L., Szallasi, Zoltan, Johansen, Julia S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264968/ https://www.ncbi.nlm.nih.gov/pubmed/35805022 http://dx.doi.org/10.3390/cancers14133250

Ejemplares similares

Prognostic value of circulating proteins in patients undergoing surgery for pancreatic cancer
por: Lindgaard, Sidsel C., et al.
Publicado: (2022)

Determination of temporal reproducibility and variability of cancer biomarkers in serum and EDTA plasma samples using a proximity extension assay
por: Christensen, Troels D., et al.
Publicado: (2022)

Development and validation of circulating protein signatures as diagnostic biomarkers for biliary tract cancer
por: Christensen, Troels D., et al.
Publicado: (2022)

Combining sCD163 with CA 19-9 Increases the Predictiveness of Pancreatic Ductal Adenocarcinoma
por: Stuhr, Liva K., et al.
Publicado: (2023)

Protein Signatures and Individual Circulating Proteins, including IL-6 and IL-15, Associated with Prognosis in Patients with Biliary Tract Cancer
por: Christensen, Troels D., et al.
Publicado: (2023)

Pre- and Perioperative Inflammatory Biomarkers in Older Patients Resected for Localized Colorectal Cancer: Associations with Complications and Prognosis
por: Dolin, Troels Gammeltoft, et al.
Publicado: (2021)

Collagen Biomarkers Quantify Fibroblast Activity In Vitro and Predict Survival in Patients with Pancreatic Ductal Adenocarcinoma
por: Nissen, Neel I., et al.
Publicado: (2022)

Inflammatory Biomarker Score Identifies Patients with Six-Fold Increased Risk of One-Year Mortality after Pancreatic Cancer
por: Kjaergaard, Alisa D., et al.
Publicado: (2021)

Ultrasensitive plasma ctDNA KRAS assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal adenocarcinoma
por: Chen, Inna, et al.
Publicado: (2017)

Intratumoral T-cell and B-cell receptor architecture associates with distinct immune tumor microenvironment features and clinical outcomes of anti-PD-1/L1 immunotherapy
por: Schina, Aimilia, et al.
Publicado: (2023)

High serum levels of the C-propetide of type V collagen (PRO-C5) are prognostic for short overall survival in patients with pancreatic ductal adenocarcinoma
por: Nissen, Neel I., et al.
Publicado: (2023)

A major genetic accelerator of cancer diagnosis: rs867228 in FPR1
por: Sztupinszki, Zsofia, et al.
Publicado: (2021)

Replicative stress in gastroesophageal adenocarcinoma is associated with chromosomal instability and sensitivity to DNA damage response inhibitors
por: Sahgal, Pranshu, et al.
Publicado: (2023)

Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer
por: Schultz, Nicolai A., et al.
Publicado: (2013)

Promoter hypermethylation of SFRP1 as a prognostic and potentially predictive blood-based biomarker in patients with localized pancreatic ductal adenocarcinoma
por: Stubbe, Benjamin Emil, et al.
Publicado: (2023)

Measuring KRAS Mutations in Circulating Tumor DNA by Droplet Digital PCR and Next-Generation Sequencing
por: Demuth, Christina, et al.
Publicado: (2018)

Circulating microRNAs as Prognostic and Predictive Biomarkers in Patients with Colorectal Cancer
por: Schou, Jakob Vasehus, et al.
Publicado: (2016)

A loss-of-function polymorphism in ATG16L1 compromises therapeutic outcome in head and neck carcinoma patients
por: Le Naour, Julie, et al.
Publicado: (2022)

PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer
por: Dillon, Kasia M., et al.
Publicado: (2022)

A Randomized Placebo-Controlled Phase 2 Study of Gemcitabine and Capecitabine with or without T-ChOS as Adjuvant Therapy in Patients with Resected Pancreatic Cancer (CHIPAC)
por: Theile, Susann, et al.
Publicado: (2022)

Identification and Validation of Circulating Micrornas as Prognostic Biomarkers in Pancreatic Ductal Adenocarcinoma Patients Undergoing Surgical Resection
por: Gablo, Natalia, et al.
Publicado: (2020)

Characterization of unique PMEPA1 gene splice variants (isoforms d and e) from RNA Seq profiling provides novel insights into prognostic evaluation of prostate cancer
por: Sharad, Shashwat, et al.
Publicado: (2020)

Plasma Kallikrein-Activated TGF-β Is Prognostic for Poor Overall Survival in Patients with Pancreatic Ductal Adenocarcinoma and Associates with Increased Fibrogenesis
por: Pedersen, Rasmus S., et al.
Publicado: (2022)

Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer
por: Sztupinszki, Zsofia, et al.
Publicado: (2018)

AHRR (cg05575921) methylation extent of leukocyte DNA and lung cancer survival
por: Kemp Jacobsen, Katja, et al.
Publicado: (2019)

Circulating Nucleic Acids as Novel Biomarkers for Pancreatic Ductal Adenocarcinoma
por: McGowan, Ryan, et al.
Publicado: (2022)

Portal Venous Circulating Tumor Cells Undergoing Epithelial-Mesenchymal Transition Exhibit Distinct Clinical Significance in Pancreatic Ductal Adenocarcinoma
por: Pan, Yujin, et al.
Publicado: (2021)

A model for the detection of pancreatic ductal adenocarcinoma circulating tumor cells
por: Alexander, Matthew S., et al.
Publicado: (2018)

Longitudinal Study of Circulating Biomarkers in Patients with Resectable Pancreatic Ductal Adenocarcinoma
por: Dopico, Pablo J., et al.
Publicado: (2022)

Detection of circulating tumor cells in blood of pancreatic ductal adenocarcinoma patients
por: Mayado, Andrea, et al.
Publicado: (2020)

Lack of association of CD44-rs353630 and CHI3L2-rs684559 with pancreatic ductal adenocarcinoma survival
por: Gentiluomo, Manuel, et al.
Publicado: (2021)

Colon cancer subtypes: concordance, effect on survival and selection of the most representative preclinical models
por: Sztupinszki, Zsófia, et al.
Publicado: (2016)

Circulating Chromogranin A Is Cleaved Into Vasoregulatory Fragments in Patients With Pancreatic Ductal Adenocarcinoma
por: Reni, Michele, et al.
Publicado: (2020)

Circulating Monocytes Serve as Novel Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma Patients
por: Hansen, Frederik J., et al.
Publicado: (2023)

Circulating tumor DNA: toward evolving the clinical paradigm of pancreatic ductal adenocarcinoma
por: Topham, James T., et al.
Publicado: (2023)

Liquid biopsy in pancreatic ductal adenocarcinoma: current status of circulating tumor cells and circulating tumor DNA
por: Lee, Jee‐Soo, et al.
Publicado: (2019)

Podocalyxin Is a Marker of Poor Prognosis in Pancreatic Ductal Adenocarcinoma
por: Saukkonen, Kapo, et al.
Publicado: (2015)

RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancer
por: Miao, Chenkui, et al.
Publicado: (2022)

E3 ligase RFWD3 is a novel modulator of stalled fork stability in BRCA2-deficient cells
por: Duan, Haohui, et al.
Publicado: (2020)

PROX1 and β-catenin are prognostic markers in pancreatic ductal adenocarcinoma
por: Saukkonen, Kapo, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_hqo8ru00k267hc92ms41lbh9rc